Virtual Workshop on Rheumatoid Arthritis, Asthma & COPD: Characterization of the Patients, New Evidence, Research Needs and Opportunities
Overview
Organization: National Heart Lung and Blood Institute
Start Date: 02/2021
End Date: 02/2021
Primary Goal: Goal 4: Increase and sustain research to better understand the prevention, pathogenesis, diagnosis, treatment, and management of COPD.
Secondary Goal(s):
Objective(s):
- Improve methods for earliest detection and diagnosis and develop effective strategies for preventing the onset and progression of COPD
- Develop personalized medicine for COPD based on the pathogenesis and clinical heterogeneity
- Promote research that can lead to strategies that help prevent the onset and progression of COPD and improve the quality of COPD care and management
Collaboration: We worked alone
Activity Type: Event, Research
Activity Description
Lung disease is a well-known comorbidity in rheumatoid arthritis (RA). Although interstitial lung disease (ILD) is the primary manifestation of RA in the lungs, there is strong emerging evidence that airway diseases including asthma and chronic obstructive pulmonary disease (COPD) affect both the course and mortality of RA. The ‘pre-RA’ period in which genetic and environmental factors combine to trigger and propagate autoimmunity before arthritis develops is also actively being investigated; indeed, there are several ongoing trials worldwide set to explore methods to prevent RA. Mucosal processes, including lung/airway immuno-pathobiology, are thought to play a key role in pre-RA and could represent an area to target for disease prevention and/or treatment.Workshop Goals
• Describe the type, prevalence and impact of airway disease in RA.
• Describe the evidence supporting a possible role for airway disease in the etiopathogenesis of RA development, even in the pre-RA phase.
• Compare and contrast the biology and risk factors for airway disease in RA as well as non-RA conditions to identify potential shared mechanisms of disease that could be leveraged to improve diagnosis and treatment.
• Identify imaging and non-imaging methods and biomarkers for assessing airway disease in RA.
• Understand current and pipeline therapies for asthma and COPD and airway disease in RA, and how known therapies, or gaps, may help to move the field toward better treatments for airway disease with or without RA.
• Develop a meeting summary that can be published and used to drive forward research in the area of airway disease across the spectrum of RA development.
Audience
General Audience: Researchers
Focused Audience: n/a
Program Reach: National
Type of Area: Urban, Suburban, Rural
Setting: Online
Cost and Funding Sources
The workshop was funded through the National Heart Lung and Blood Institute in collaboration with the National Institute of Arthritis and Musculoskeletal and Skin Diseases.Impact Analysis
Educated audience about advances in COPD research.Advice or Lessons Learned
N/AContact Information
National Heart Lung and Blood Institute
Program Analyst
Bethesda
Maryland